Vaxcyte Inc experienced a significant boost in its stock price following a successful capital raise and positive clinical data.
Vaxcyte Inc (NASDAQ:PCVX) saw its stock price surge by 9.79% yesterday, closing at CA$71.38. This increase was largely driven by the company's announcement of closing a $1.15 billion public offering, which included common stock and convertible senior notes.
Advertisement
Vaxcyte Inc
PCVX.US
PCVX.US
Vaxcyte Inc
WealthAwesomeMarket cap
$11.15B
52W high
$90.75
52W low
$39.87
1W change
+26.38%
Beta
1.23
Analyst Price Targets
Based on 11 analysts covering PCVX · as of Oct 9, 2026
Wall Street analysts forecast PCVX stock price to rise 63.9% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
C$117.00
+63.9% Upside
Previously C$110.88 on Oct 8, 2026
Current Price
C$71.38
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCVX's historical volatility
30-Day Vol
92.8%
Annualized
90-Day Vol
65.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$85.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$75.76 | C$55.00 – C$104.36 |
| 60 trading days | C$80.40 | C$51.12 – C$126.47 |
| 90 trading days | C$85.34 | C$49.00 – C$148.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The capital raise positions Vaxcyte to fund its clinical development programs, particularly for its VAX-31 pneumococcal vaccine candidate, which is currently undergoing important trials.
$1.15 billion
The total gross proceeds from Vaxcyte's recent public offerings, which will support its clinical development and manufacturing scale-up.
Bull case
With the successful completion of its public offerings, Vaxcyte is now well-positioned to advance its clinical trials and enhance its manufacturing capabilities. This could lead to a successful launch of its vaccine candidates and a larger share of the vaccine market.
Bear case
Investors should stay cautious, as the company's future performance relies heavily on the outcomes of ongoing clinical trials. Any disappointing results could negatively impact the stock price.
Strong Financial Backing
Advertisement
Vaxcyte's recent capital raise of $1.15 billion through public offerings strengthens the company’s ability to support its clinical programs, especially for its VAX-31 vaccine. This funding will help with ongoing trials and the necessary manufacturing scale-up to meet potential demand.
Positive Clinical Momentum
The stock's surge was also supported by recent positive Phase 3 data for Vaxcyte's VAX-31 pneumococcal vaccine candidate. With a strong year-to-date performance and positive sentiment around its clinical trials, Vaxcyte is gaining attention among investors.
Future Considerations
While the recent surge is promising, investors should keep an eye on the results of ongoing trials. Any setbacks in clinical data could lead to volatility in the stock price, making it crucial for stakeholders to stay informed about Vaxcyte's developments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
